Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Developmental therapeutics

526O - High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours


20 Sep 2020


Proffered Paper - Developmental therapeutics


Clinical Research;  Immunotherapy;  Rare Cancers

Tumour Site


Benoit Rousseau


Annals of Oncology (2020) 31 (suppl_4): S462-S504. 10.1016/annonc/annonc271


B.J. Rousseau1, I. Bieche2, E. Pasmant3, V. Simmet4, N. Hamzaoui3, J. Masliah-Planchon5, D. Pouessel6, A. Bruyas7, P. Augereau4, J. Grob8, F. Rolland9, E. Saada-Bouzid10, R. Cohen11, O. Bouche12, N. Hoog-Labouret13, F. Legrand13, C. Simon14, A. Lamrani-Ghaouti15, S. Chevret16, A. Marabelle17

Author affiliations

  • 1 Solid Tumors, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 Molecular Biology, Institut Curie, 75005 - Paris/FR
  • 3 Service De Génétique Et Biologie Moléculaires, Hupc, Ap-hp, Cochin Hospital, 75005 - Paris/FR
  • 4 Department Of Medical Oncology, Institut de Cancérologie de l'Ouest (ICO), 49100 - Angers/FR
  • 5 Genetics, Institut Curie, Paris/FR
  • 6 Department Of Medical Oncology, Institut Claudius Regaud / Cancer Comprehensive Center, Midi-Pyrénées/FR
  • 7 Department Of Medical Oncology, Hôpital de la Croix-Rousse, 69317 - Lyon/FR
  • 8 Dermatology And Oncology, Hôpital de la Timone, 13005 - Marseille/FR
  • 9 Department Of Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 10 Medical Oncology, Centre Anticancer Antoine Lacassagne, 06189 - Nice/FR
  • 11 Medical Oncology Department, Hôpital Saint-Antoine, 75571 - Paris/FR
  • 12 Gastroenterology And Digestive Oncology, CHU de Reims - Hôpital Robert Debré, 51092 - Reims/FR
  • 13 Research And Innovation, Institut National du Cancer, 92500 - Boulogne-Billancourt/FR
  • 14 R&d Department, UNICANCER, 75654 - Paris/FR
  • 15 R&d, UNICANCER, 75654 - Paris/FR
  • 16 Biostatisitics, Hopital St Louis, 75011 - Paris/FR
  • 17 Drug Development Department, Institut Gustave Roussy, 94805 - Villejuif/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 526O


Hotspot edPOLE mutations (mut) generate proofreading defects and hypermutated genomic profiles. While rare in the advanced setting, most edPOLE mut pathogenicity and derived sensitivity to anti-PD-1 (aPD1) agents remains unclear. We aimed to investigate the efficacy of nivolumab in MMRp tumours with edPOLE mut.


ACSé immunotherapy is a nationwide program launched by the French National Cancer Institute (INCa) and sponsored by the French network of comprehensive cancer centres (Unicancer) investigating the efficacy and tolerance of aPD1 in multiple phase II single arm cohorts in rare tumours. We report here the initial results of the edPOLE cohort, which is the first trial selecting patients on a prospective assessment of missense POLE mut pathogenicity by an ad hoc molecular tumour board. nivolumab (240 mg IV q2w) was administered until disease progression (PD), toxicity or for up to 2 years. The primary endpoint was the objective response rate (ORR) assessed by RECIST v1.1 at 12 weeks.


From Apr 2018 to Jan 2020, 15 pts (mean age, 59 years) were included with colorectal (6), endometrial (4), gastric (2), pancreas (1), biliary (1) and glial (1) tumours. Mean number of previous lines of treatment was 2.7. Median follow up was 74 days (Q1-Q3= 40.5-188.5). At the date of submission, nivolumab safety was in accordance with data reported in other tumour types. ORR at 12 weeks in 10 evaluable patients was 30% (PR: n=3; SD: n=4; PD: n=3). Pathogenicity of edPOLE mut was confirmed by the ad hoc committee in 7 cases (47%): 2 P286R, 2 N363K, 2 V411L, 1 A463V. In the pathogenic mut group, ORR was 50% (3/6), disease control rate was 83% (5/6) and median progression-free survival (mPFS) was 161 days. Responses were observed in MMRp colorectal and endometrial cancers with P286R and V411L mutations. Conversely, in the non-pathogenic group (n=4), only 2 SD were observed as best response and 2 pts died before first evaluation. mPFS in this group was 47 days.


We report the first clinical trial assessing aPD1 in POLE mutated MMRp tumours. Nivolumab activity appears promising in edPOLE mutated MMRp advanced cancer pts but activity is limited to pathogenic mutations, underlining the need for individual mutational functional assessment by a molecular tumour board. We will include the tumour evaluation of the last 5 additional patients at the ESMO 2020 Virtual Congress.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study





B.J-C. Rousseau: Advisory/Consultancy, Speaker Bureau/Expert testimony: Bayer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Travel/Accommodation/Expenses: Servier; Travel/Accommodation/Expenses: Astellas; Speaker Bureau/Expert testimony: Gilead. V. Simmet: Honoraria (self): Lilly; Honoraria (self): Servier; Travel/Accommodation/Expenses: Amgen; Travel/Accommodation/Expenses: Novartis. D. Pouessel: Honoraria (self): Ipsen; Honoraria (self), Honoraria (institution): BMS; Honoraria (self), Honoraria (institution), Travel/Accommodation/Expenses: AstraZenca; Honoraria (self): Sanofi; Honoraria (self), Travel/Accommodation/Expenses: Pfizer; Honoraria (self): Merck; Honoraria (self): Astellas; Honoraria (self), Honoraria (institution), Travel/Accommodation/Expenses: Janssen; Honoraria (institution): MSD; Honoraria (institution): Incyte. A. Bruyas: Speaker Bureau/Expert testimony: BMS. F. Rolland: Advisory/Consultancy: Merck KGaA; Advisory/Consultancy: MSD; Advisory/Consultancy: BMS. E. Saada-Bouzid: Advisory/Consultancy: Merck KGaA; Advisory/Consultancy: MSD; Advisory/Consultancy: BMS. R. Cohen: Honoraria (self): Servier; Honoraria (self): Amgen; Honoraria (self): Sanofi. O. Bouche: Honoraria (self), Travel/Accommodation/Expenses: Roche; Honoraria (self): Merck; Honoraria (self), Speaker Bureau/Expert testimony: Amgen; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Bayer; Speaker Bureau/Expert testimony: Pierre Fabre; Speaker Bureau/Expert testimony: Servier; Travel/Accommodation/Expenses: Lilly. A. Marabelle: Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: Roche/Genentech; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Research grant/Funding (institution): Pfizer; Advisory/Consultancy, Research grant/Funding (institution): Lytix pharma; Research grant/Funding (institution): Eisai; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca/Medimmune; Research grant/Funding (institution): Tesaro; Research grant/Funding (institution): Chugai; Advisory/Consultancy: GSK; Advisory/Consultancy: Innate pharma; Advisory/Consultancy: Novartis; Advisory/Consultancy: Bayer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.